Addressing Sex as a Biological Variable in Preclinical Models of Lung Disease: An Official American Thoracic Society Research Statement
Authors:
- Krithika LingappanKLKrithika Lingappan
- Isaac Kirubakaran SundarISIsaac Kirubakaran Sundar
- Y. S. PrakashYPY. S. Prakash
- Elizabeth F. RedenteERElizabeth F. Redente
- Don D. SinDSDon D. Sin
- MeiLan K. HanMHMeiLan K. Han
- Tim LahmTLTim Lahm
- Vera P. KrymskayaVKVera P. Krymskaya
- Darrell N. KottonDKDarrell N. Kotton
- Hrishikesh S. KulkarniHKHrishikesh S. Kulkarni
- Raksha JainRJRaksha Jain
- Melanie KönigshoffMKMelanie Königshoff
Open Access
- 1 August 2025
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1346-1368
Abstract
Background: Pulmonary diseases have sex-specific predilections across the lifespan. The rigor of preclinical research is paramount to ensure the reproducibility and applicability of findings to clinical studies. The overarching goal was to identify current research gaps and the need for consideration of sex as a biological variable (SABV) in preclinical pulmonary research. The objective was to provide a roadmap and the best standards to incorporate and investigate the role of biological sex in preclinical models of lung diseases. Methods: A multidisciplinary working group of 17 international investigators from the American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, external content experts, and researchers engaged in lung basic and translational research. They reviewed the literature, identified critical knowledge gaps, and provided recommendations. Results: The research statement provides an updated summary of the currently available evidence on the standards of SABV research in preclinical models and then offers specific research recommendations focused on the needs of researchers in the pulmonary field. The statement identifies knowledge gaps and develops guidance for experimental design and key considerations for incorporating SABV in two major topic areas: 1) in vivo; and 2) in vitro models. Furthermore, the group developed a checklist to guide researchers in including SABV in preclinical studies. Conclusions: This statement provides a roadmap for the investigation of SABV in preclinical models. This will increase the applicability of findings to both sexes, uncover sex-biased mechanisms in lung diseases, and identify novel therapeutic targets.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL144775)
- National Heart, Lung, and Blood Institute (R01HL146395)
This publication has 256 references indexed in Scilit:
- Global Burden of Chronic Obstructive Pulmonary Disease Through 2050JAMA Network Open, 2023
- Sex and Gender Differences in Lung Disease2021
- Animal models of rheumatoid arthritis‐associated interstitial lung diseaseImmunity, Inflammation and Disease, 2020
- Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure2019
- Confounding influence of tamoxifen in mouse models of Cre recombinase-induced gene activity or modulationArchives of Toxicology, 2018
- Sexual dimorphism of microglia and synapses during mouse postnatal developmentDevelopmental Neurobiology, 2018
- A general theory of sexual differentiationJournal of Neuroscience Research, 2016
- Sex Steroids Influence Brain-Derived Neurotropic Factor Secretion From Human Airway Smooth Muscle CellsJournal of Cellular Physiology, 2015
- Brief Report: Testosterone Is Protective in the Sexually Dimorphic Development of Arthritis and Lung Disease in SKG MiceArthritis & Rheumatism, 2013
- Involvement of Apoptosis in 4-Vinylcyclohexene Diepoxide- Induced Ovotoxicity in RatsToxicology and Applied Pharmacology, 1996